Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy
Open-label, no control groupHumans
- Design
- Open-label, no control group
- Subjects
- 20 patients with multiple myeloma and painful neuropathy from thalidomide and bortezomib
- Dose used in the study
- PEA 300 mg twice daily
- Duration
- 2 months
- What was measured
- Pain and warmth thresholds, and motor and sensory nerve fibre function and laser-evoked potentials (the last two measured by blinded examiners), before and after PEA 300 mg twice daily for two months.
What the authors reported
Pain and all neurophysiological measures of myelinated A-alpha, A-beta and A-delta fibres improved (p < 0.05), though none returned to normal. Warmth thresholds, which reflect unmyelinated fibres, did not change.
Limits of this study
No control group; the authors note a placebo effect could explain the pain change. 20 patients. The objective nerve measures were assessed blind, which is the study's strength.
Source
PubMed 22229320 · doi:10.2174/187152711799219307
Entry checked against the abstract, supplied by Devlin on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.